HCW Biologics (NASDAQ:HCWB) CFO Rebecca Byam Purchases 14,235 Shares

HCW Biologics Inc. (NASDAQ:HCWB) CFO Rebecca Byam acquired 14,235 shares of the company’s stock in a transaction on Friday, May 22nd. The stock was acquired at an average cost of $1.41 per share, with a total value of $20,071.35. Following the completion of the purchase, the chief financial officer directly owned 57,245 shares in the company, valued at approximately $80,715.45. This represents a 33.10% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

HCW Biologics Stock Down 26.0%

Shares of NASDAQ:HCWB opened at $1.94 on Thursday. HCW Biologics Inc. has a 52 week low of $0.25 and a 52 week high of $8.75. The stock has a market capitalization of $13.06 million, a P/E ratio of -0.21 and a beta of 1.13. The firm has a fifty day simple moving average of $0.72 and a two-hundred day simple moving average of $1.15.

HCW Biologics (NASDAQ:HCWB) last released its quarterly earnings results on Thursday, May 14th. The company reported $0.37 EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.81. HCW Biologics had a negative net margin of 34.73% and a negative return on equity of 486.87%. The firm had revenue of $6.54 million during the quarter, compared to analysts’ expectations of $6.54 million.

Analyst Upgrades and Downgrades

HCWB has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HCW Biologics in a research note on Tuesday, April 21st. Wall Street Zen raised shares of HCW Biologics to a “hold” rating in a research note on Saturday, May 23rd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $35.00.

Institutional Investors Weigh In On HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Armistice Capital LLC acquired a new stake in HCW Biologics Inc. (NASDAQ:HCWB) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned 9.15% of HCW Biologics at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.96% of the company’s stock.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.